Company Ampliphi Biosciences Corp Nyse
Equities
APHB
US03211P2020
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pathogen-specific Bacteriophage Therapeutics
100.0
%
| 6 | 100.0 % | 5 | 100.0 % | -17.77% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States and Australia
100.0
%
| 6 | 100.0 % | 5 | 100.0 % | -17.77% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Deborah Birx
CEO | Chief Executive Officer | 68 | 23-07-10 |
Richard Rychlik
DFI | Director of Finance/CFO | 68 | 23-09-04 |
Mina Pastagia
CTO | Chief Tech/Sci/R&D Officer | - | 20-10-25 |
Bryan Kadotani
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 20-02-11 | |
Joseph Patti
BRD | Director/Board Member | 60 | 19-05-08 |
Jules Haimovitz
BRD | Director/Board Member | 73 | 21-03-31 |
Odysseas Kostas
BRD | Director/Board Member | 49 | 20-02-11 |
Robin Kramer
CHM | Chairman | 58 | 20-12-07 |
Todd Peterson
BRD | Director/Board Member | 66 | 19-10-09 |
Deborah Birx
CEO | Chief Executive Officer | 68 | 23-07-10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 36,154,617 | 10,736,770 ( 29.70 %) | 0 | 29.70 % |
Company contact information
![address Ampliphi Biosciences Corp(APHB)](https://cdn.zonebourse.com/static/address/23437223.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B |